FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.